Results 171 to 180 of about 15,404 (212)

Dual PTP1B/DPP4 Inhibitory Potential of <i>Agathosma betulina</i>, <i>Cymbopogon citratus</i>, and <i>Artemisia afra</i>: Structure-Based Modeling of Phytochemical Leads and Essential Oil Bioassays. [PDF]

Comput Struct Biotechnol J
Adedirin O, Sabiu S.
europepmc   +1 more source

Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countries. [PDF]

J Manag Care Spec Pharm
Gabriel N, Martin K, Cousin EM, Li KH, Grueger J, Sullivan SD.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sitagliptin

Drugs, 2012
Sohita Dhillon, Dhillon Sohita
exaly   +5 more sources

Sitagliptin

Drugs, 2007
Sitagliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, improves glycaemic control by inhibiting DPP-4 inactivation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. This increases active incretin and insulin levels, and decreases glucagon levels and post-glucose-load glucose excursion.
Daniel Drucker, Chris Easley, Peter Kirkpatrick   +2 more
openaire   +3 more sources

Sitagliptin: a review

Expert Opinion on Pharmacotherapy, 2011
The ever-increasing burden of type 2 diabetes mellitus (T2DM) and inadequate control in the majority of patients has led to a quest for newer therapeutic options. There have been recent exciting advances in the treatment of T2DM, targeting the enteroinsular axis with incretin-based therapies that include the dipeptidyl peptidase IV (DPP-IV) inhibitors ...
Sreevidya, Subbarayan, Mark, Kipnes
openaire   +2 more sources

Sitagliptin

Reactions Weekly, 2021
  +4 more sources

Metformin/sitagliptin/sitagliptin

Reactions Weekly, 2021
openaire   +1 more source

Sitagliptin and Angioedema

Annals of Internal Medicine, 2017
Robin, Arcani, Sonia, Martinez, Stéphane, Gayet   +2 more
openaire   +2 more sources